Inhibikase Therapeutics, Inc. Other Current Liabilities
Inhibikase Therapeutics, Inc. (IKT) had Other Current Liabilities of $2.74 million as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2023-11-14
- 2023-09-30: Other Liabilities, Current $2.74M.
- 2023-06-30: Other Liabilities, Current $2.73M.
- 2023-03-31: Other Liabilities, Current $2.66M.
- 2022-09-30: Other Liabilities, Current $3.07M.
| Period end | Other Liabilities, Current |
|---|---|
| 2023-09-30 | $2.74M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $2.73M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $2.66M 10-Q · filed 2023-05-15 |
| 2022-09-30 | $3.07M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |